openPR Logo
Press release

Deadline on Dec. 7th coming up in Lawsuit filed for Investors in Mesoblast Limited (OTC: MEOBF)

12-02-2020 11:32 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

A Deadline is coming up on December 7, 2020  in the lawsuit for certain investors in Mesoblast Limited (OTC: MEOBF).

A Deadline is coming up on December 7, 2020 in the lawsuit for certain investors in Mesoblast Limited (OTC: MEOBF).

A deadline is coming up on December 7, 2020 in the lawsuit filed for certain investors of Mesoblast Limited (OTC: MEOBF) over alleged securities laws violations by Mesoblast Limited (OTC: MEOBF).

Investors who purchased shares of Mesoblast Limited (OTC: MEOBF) have certain options and there are strict and short deadlines running. Deadline: December 7, 2020. OTC: MEOBF stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

According to the complaint filed in the U.S. District Court for the Southern District of New York the plaintiff alleges on behalf of purchasers of Mesoblast Limited (OTC: MEOBF) common shares between April 16, 2019 and October 1, 2020, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between April 16, 2019 and October 1, 2020, the Defendants failed to disclose to investors, that comparative analyses between Mesoblast’s Phase 3 trial and three historical studies did not support the effectiveness of remestemcel-L for steroid refractory aGVHD due to design differences between the four studies, that, as a result, the FDA was reasonably likely to require further clinical studies, that, as a result, the commercialization of remestemcel-L in the U.S. was likely to be delayed, and that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Those who purchased shares of Mesoblast Limited (OTC: MEOBF) have certain options and should contact the Shareholders Foundation.

Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Deadline on Dec. 7th coming up in Lawsuit filed for Investors in Mesoblast Limited (OTC: MEOBF) here

News-ID: 2201112 • Views:

More Releases from Shareholders Foundation

Lawsuit for Investors in Sonder Holdings Inc. (NASDAQ: SOND) filed in effort to recover losses
Lawsuit for Investors in Sonder Holdings Inc. (NASDAQ: SOND) filed in effort to …
An investor, who purchased shares of Sonder Holdings Inc. (NASDAQ: SOND), filed a lawsuit over alleged violations of Federal Securities Laws by Sonder Holdings Inc in connection with certain allegedly false and misleading statements. Investors who purchased shares of Sonder Holdings Inc. (NASDAQ: SOND) have certain options and for certain investors are short and strict deadlines running. Deadline: June 10, 2024. NASDAQ: SOND investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com
Lawsuit filed for Investors in Ocugen, Inc. (NASDAQ: OCGN) in effort to recover losses
Lawsuit filed for Investors in Ocugen, Inc. (NASDAQ: OCGN) in effort to recover …
An investor, who purchased shares of Ocugen, Inc. (NASDAQ: OCGN), filed a lawsuit i over alleged violations of Federal Securities Laws by Ocugen, Inc.. Investors who purchased shares of Ocugen, Inc. (NASDAQ: OCGN) have certain options and for certain investors are short and strict deadlines running. Deadline: June 10, 2024. NASDAQ: OCGN investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. Malvern, PA based Ocugen, Inc., a
Investors who lost money with shares of Evolv Technologies Holdings, Inc. (NASDAQ: EVLV) should contact the Shareholders Foundation in connection with Lawsuit
Investors who lost money with shares of Evolv Technologies Holdings, Inc. (NASDA …
An investor, who purchased shares of Evolv Technologies Holdings, Inc. (NASDAQ: EVLV), filed a lawsuit in the U.S. District Court for the District of Massachusetts over alleged violations of Federal Securities Laws by Evolv Technologies Holdings, Inc. f/k/a NewHold Investment Corp. Investors who purchased shares of Evolv Technologies Holdings, Inc. (NASDAQ: EVLV) have certain options and for certain investors are short and strict deadlines running. Deadline: May 24, 2024. NASDAQ: EVLV
Investigation announced for Investors who purchased shares of Comtech Telecommunications Corp. (NASDAQ: CMTL) over possible Violations of Securities Laws
Investigation announced for Investors who purchased shares of Comtech Telecommun …
Comtech Telecommunications Corp is under investigation over potential securities laws violations in connection with certain financial statements. Investors who purchased shares of Comtech Telecommunications Corp. (NASDAQ: CMTL), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on whether a series of statements by Comtech Telecommunications Corp. regarding its business, its prospects and its operations were materially false

All 5 Releases


More Releases for Mesoblast

Umbilical Cord Blood (UCB) Stem Cell Market Growth, Industry Research and Develo …
The research reports on the "Umbilical Cord Blood (UCB) Stem Cell Market" report give a detailed overview of the factors affecting the global scope of business. Information in the global Umbilical Cord Blood (UCB) Stem Cell market report provides forecast data for future market growth in global demand and supply. The report initially provides a basic overview of the segments, market dynamics, applications, and technologies in which the report explores
Investigation announced for Investors of Mesoblast Limited (OTC: MEOBF) over pot …
An investigation on behalf of current long-term investors in shares of Mesoblast Limited (OTC: MEOBF) concerning potential breaches of fiduciary duties by certain directors and officers of Mesoblast Limited was announced. Investors who are current long term investors in Mesoblast Limited (OTC: MEOBF) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term
Investigation announced for Investors in shares of Mesoblast Limited (OTC: MEOBF …
An investigation on behalf of investors of Mesoblast Limited (OTC: MEOBF) shares over potential securities laws violations by Mesoblast Limited and certain of its directors and officers in connection with certain financial statements was announced. Investors who purchased shares of Mesoblast Limited (OTC: MEOBF), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on possible claims on
Stem Cell Therapy Market Key Players : Mesoblast Ltd., Celgene Corporation, Aast …
Stem cells are most vital cells found in both humans and non-human animals. Stem cells are also known as centerpiece of regenerative medicine. Regenerative medicines have capability to grow new cells and replace damaged and dead cells. Stem cell is the precursors of all cells in the human body. It has the ability to replicate itself and repair and replace other damaged tissues in the human body. In addition, stem
Cell Therapy Market Overview and Forecast Report 2019| Dendreon, Mesoblast, Veri …
The report presented here is a comprehensive research study that explores key aspects of the global Cell Therapy market, including market dynamics, segmentation, competition, and regional growth. Each section of the report reveals critical information about the global Cell Therapy market that could be used to ensure strong growth in the coming years. All of the segments included in the report are studied on the basis of different factors such
Stem Cell Therapy Market Size 2018 Athersys, Mesoblast, Celgene, Vcanbio
Stem Cell Therapy Market Research 2018 A market study "Global Stem Cell Therapy Market" examines the performance of the Stem Cell Therapy market 2018. It encloses an in-depth Research of the Stem Cell Therapy market state and the competitive landscape globally. This report analyzes the potential of Stem Cell Therapy market in the present and the future prospects from various angles in detail. The Global Stem Cell Therapy Market 2018 report includes